Patents by Inventor Andrew P. Hinck

Andrew P. Hinck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ONCOLYTIC VIRUSES ENCODING RECOMBINANT TRANSFORMING GROWTH FACTOR (TGF)-BETA MONOMERS AND USES THEREOF
    Publication number: 20240011046
    Abstract: Oncolytic viruses encoding a recombinant form of TGF-? engineered to prevent homodimerization and recruitment of TGF-? receptor I are described. The engineered TGF-? monomers function as dominant-negative TGF-? inhibitors. Oncolytic viruses encoding a TGF-? monomer can be used for cancer immunotherapy to inhibit the immunosuppressive tumor microenvironment.
    Type: Application
    Filed: August 27, 2021
    Publication date: January 11, 2024
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Greg M. Delgoffe, Andrew P. Hinck, Kristin DePeaux
  • Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
    Patent number: 7795389
    Abstract: Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGF?) antagonists are disclosed, where the agents and/or antagonists include a therapeutically effective amount of a combination of therapeutically active portions of sRII and therapeutically active portions of sRIII or a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII. Methods for preventing, treating and/or ameliorating the symptoms of cancer are also disclosed based on administering an effective amount of a composition of this invention.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: September 14, 2010
    Assignee: The Board of Regents of the University of Texas System
    Inventors: LuZhe Sun, Andrew P. Hinck